Trials / Completed
CompletedNCT02746471
Reveal LINQ Registry
Medtronic Reveal LINQ Insertable Cardiac Monitor Registry
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,604 (actual)
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The Reveal LINQ Registry will generate reliable long-term "real world" data of product performance, economic valuation, site-of-service procedural information.
Detailed description
The study is a prospective, non-randomized, observational, multi-center, global study. The study will characterize clinical actions initiated by Reveal LINQ arrhythmia detection and estimate procedure-related acute infection rate. Approximately 1,500 subjects will be implanted with a Reveal LINQ ICM and undergo continuous remote monitoring and be followed prospectively from insertion through 36 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Reveal LINQ |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2021-06-04
- Completion
- 2021-06-04
- First posted
- 2016-04-21
- Last updated
- 2022-07-18
- Results posted
- 2022-07-18
Locations
48 sites across 9 countries: United States, Belgium, Greece, Israel, Italy, Japan, Netherlands, Portugal, Saudi Arabia
Source: ClinicalTrials.gov record NCT02746471. Inclusion in this directory is not an endorsement.